Who is sponsoring NCT03321032?

NCT03321032 is sponsored by Spanish Society of Cardiology.

What drugs are being tested in NCT03321032?

Interventions in NCT03321032: Polymer-free amphilimus-eluting stents, Biolinx Polymer-based zotarolimus-eluting stents.

What condition does NCT03321032 study?

NCT03321032 studies Coronary Artery Disease, Diabetes Mellitus.

Is NCT03321032 still recruiting?

NCT03321032 is currently status unknown. Last updated 19 January 2021.

Last reviewed 2021-01-19 · How we verify

NCT03321032: SUGAR

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Second-generation Drug-eluting Stents in Diabetes

Status unknown Phase 4 Last updated 19 January 2021

What this trial tests

Phase 4 trial testing Polymer-free amphilimus-eluting stents in Coronary Artery Disease in 1,164 participants. Status unknown.

Timeline

19 December 2017

Primary endpoint
28 January 2021

28 January 2022

Quick facts

Lead sponsor	Spanish Society of Cardiology
Phase	Phase 4
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	1,164
Start date	19 December 2017
Primary completion	28 January 2021
Estimated completion	28 January 2022
Sites	23 locations across Spain

Drugs / interventions tested

Polymer-free amphilimus-eluting stents
Biolinx Polymer-based zotarolimus-eluting stents

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Diabetes Mellitus — all drugs for Diabetes Mellitus →

Sponsor

Spanish Society of Cardiology

Who can join

Adults 18 to 100, any sex, with Coronary Artery Disease or Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an investigator initiated randomized trial, performed under the auspices of the Spanish Society of Cardiology. It is a multicenter, international, parallel, randomized 1:1 (amphilimus-eluting stents vs zotarolimus-eluting stents) clinical trial performed exclusively in patients with diabetes mellitus. The study has an "all-comers diabetics" design. The primary-endpoint is target lesion failure at 1-year follow-up (non-inferiority design) and the co-primary end-point is target lesion failure at 2-years follow-up (superiority-design).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Amphilimus- vs. zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: the SUGAR trial.
Romaguera R, Salinas P, Gomez-Lara J, Brugaletta S, et al · · 2022 · cited 30× · PMID 34735004 · DOI 10.1093/eurheartj/ehab790
Comparison of Contemporary Drug-eluting Coronary Stents - Is Any Stent Better than the Others?
Parker W, Iqbal J. · · 2020 · cited 12× · PMID 36277668 · DOI 10.17925/hi.2020.14.1.34
Amphilimus-eluting versus zotarolimus-eluting stents in patients with diabetes mellitus and coronary artery disease: extended follow-up of the SUGAR randomised controlled trial.
Salinas P, Romaguera R, Gómez-Lara J, Brugaletta S, et al · · 2025 · cited 1× · PMID 40562528 · DOI 10.1136/heartjnl-2025-325773

Verify or expand the search:

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other Spanish Society of Cardiology trials

Trials by the same sponsor.

NCT06755801 — Nebivolol ANOCA Treatment Randomized Trial · Phase 3 · not yet recruiting
NCT05619601 — Gender Differences in Prevention Strategies and Therapeutic Adherence After Acute Myocardial Infarction · active not recruiting
NCT04674475 — OPTImized Coronary Interventions eXplaIn the bEst cliNical outcomEs · unknown
NCT05825339 — Absolute Flow for Ischemia With No Obstructive Coronary Arteries · unknown
NCT04850417 — Randomized Study of Beta-Blockers and Antiplatelets in Patients With Spontaneous Coronary Artery Dissection · Phase 4 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03321032 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Spanish Society of Cardiology
Last refreshed: 19 January 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03321032.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing